Abstract:Clustered regularly interspaced palindromic repeats (CRISPR) is a gene editing tool with tremendous therapeutic potential. Recently, ribonucleoprotein (RNP) complex‐based CRISPR systems have gained momentum due to their reduction of off‐target editing. This has coincided with the emergence of extracellular vesicles (EVs) as a therapeutic delivery vehicle due to its low immunogenicity and high capacity for manipulation. EVs are cell‐derived membranous nanoparticles which mediate the intercellular transfer of molecular components. Current technologies achieve CRISPR RNP encapsulation into EVs through EVs biogenesis, thereby avoiding unnecessary physical, chemical or biological manipulations to the vesicles directly. Herein, we identify sixteen EVs‐based CRISPR RNP encapsulation strategies, each with distinct genetic features to encapsulate CRISPR RNP. According to the molecular mechanism facilitating the encapsulation process, there are six strategies of encapsulating Cas9 RNP into virus‐like particles based on genetic fusion, seven into EVs based on protein tethering, and three based on sgRNA‐coupled encapsulation. Additionally, the incorporation of a targeting moiety to the EVs membrane surface through EVs biogenesis confers tropism and increases delivery efficiency to specific cell types. The targeting moieties include viral envelope proteins, recombinant proteins containing a ligand peptide, single‐chain fragment variable (scFv) antibodies, and integrins. However, current strategies still have a number of limitations which prevent their use in clinical trials. Among those, the incorporation of viral proteins for encapsulation of Cas9 RNP have raised issues of biocompatibility due to host immune response. Future studies should focus on genetically engineering the EVs without viral proteins, enhancing EVs delivery specificity, and promoting EVs‐based homology directed repair. Nevertheless, the integration of CRISPR RNP encapsulation and tropism technologies will provide strategies for the EVs‐based delivery of CRISPR RNP in gene therapy and disease treatment.

Controlling Circular RNA Encapsulation within Extracellular Vesicles for Gene Editing and Protein Replacement

Defining the parameters for sorting of different RNA cargo into Extracellular vesicles

Exploring Circular RNA Profile and Expression in Extracellular Vesicles.

Extracellular vesicles engineered with valency-controlled DNA nanostructures deliver CRISPR/Cas9 system for gene therapy

Efficient RNA drug delivery using red blood cell extracellular vesicles

Engineering extracellular vesicles to deliver CRISPR ribonucleoprotein for gene editing

Extracellular Vesicle Spherical Nucleic Acids

Robust genome and cell engineering via in vitro and in situ circularized RNAs

Gene Editing by Extracellular Vesicles

Circular RNA landscape in extracellular vesicles from human biofluids

Functionalized extracellular nanovesicles as advanced CRISPR delivery systems

Current and prospective strategies for advancing the targeted delivery of CRISPR/Cas system via extracellular vesicles

Clinical Applications of Extracellular Vesicle Long RNAs

A Highly Efficient Strategy for Overexpressing circRNAs.

Multimodal engineering of extracellular vesicles for efficient intracellular protein delivery

Circular Sirnas for Reducing Off-Target Effects and Enhancing Long-Term Gene Silencing in Cells and Mice

Cell-derived extracellular vesicles for CRISPR/Cas9 delivery: engineering strategies for cargo packaging and loading

CRISPR/Cas9 delivery strategies with engineered extracellular vesicles

Enhanced Extracellular Vesicle Cargo Loading via microRNA Biogenesis Pathway Modulation

Engineering circular RNA regulators to specifically promote circular RNA production

Engineered Cas9 extracellular vesicles as a novel gene editing tool